EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Site-specific heterogeneity of genomic radiosensitivity across primary tumors, regional and distant metastases in breast cancer

Pierre Loap, Gilles Crehange, Youlia Kirova

Clinical Oncology · 2026-11 · 104372

DOI: 10.1016/j.clon.2026.104372 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Oncology, 2026-11. Verfasst von Pierre Loap und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Adjuvant radiotherapy for breast cancer frequently encompasses multiple anatomical compartments, including the primary tumor bed and regional lymph node basins, yet uniform radiation doses are typically prescribed across these volumes. Genomic radiosensitivity signatures such as the Radiosensitivity Index (RSI) and the Genomic-Adjusted Radiation Dose (GARD) have been proposed to guide biologically informed radiotherapy dose personalization. However, these approaches generally rely on a single measurement obtained from the primary tumor, implicitly assuming that genomic radiosensitivity is conserved across tumor sites. Whether radiosensitivity remains stable between primary tumors, lymph node metastases, and distant metastatic sites remains poorly characterized. Materials and Methods RNA-sequencing data from the AURORA US cohort were analyzed, including 125 samples from 53 patients with primary breast tumors and metastatic samples across multiple anatomical sites. RSI was calculated using a 10-gene rank-based algorithm. External validation was performed in the independent TEX trial cohort (GSE56493), comprising 119 breast cancer deposits from 112 patients with locally advanced recurrent or metastatic disease. GARD was derived from RSI for the hypofractionated adjuvant schedule of 40.05 Gy in 15 fractions. Paired comparisons between primary tumors and metastases were performed using Wilcoxon signed-rank tests, with subgroup analyses according to PAM50 molecular subtype and metastatic location.

Results

RSI exhibited a broad continuous distribution in both primary tumors and metastatic samples. In paired analyses (n=39), RSI did not differ significantly between primary tumors and metastatic sites (p=0.169). When stratified by PAM50 subtype, RSI increased significantly from primary tumor to metastasis in basal tumors (n=15 pairs, p=0.018), whereas no significant change was observed in HER2-enriched or Luminal A tumors. Across metastatic anatomical sites, median RSI values varied, although differences did not reach statistical significance in AURORA (p=0.349). In the TEX validation cohort, RSI differed significantly across metastatic sites (n=119; p=0.030), while Luminal A metastases showed the lowest median RSI, consistent with AURORA. Among the seven patients with paired primary tumors and lymph node metastases, six had basal tumors. RSI was higher in nodal lesions than in the matched primary tumor in five of seven cases (71%). In the basal paired subgroup, median GARD was 23.6 in primary tumors and 15.4 in matched lymph node metastases; four of six basal patients had primary tumor GARD above the proposed threshold of 21 for triple-negative breast cancer, whereas the matched lymph node metastasis remained below this threshold.

Conclusion

Although genomic radiosensitivity did not differ systematically between primary and metastatic breast cancer at the cohort level, inter-compartment differences were observed across selected tumour compartments and molecular subtypes. These findings suggest that single-specimen radiosensitivity assessment may not fully capture site-associated variation in tumour radiosensitivity and support further investigation of multi-compartment genomic profiling to inform biologically guided radiotherapy dose personalization.

Zitieren

APA

Loap, P., Crehange, G., & Kirova, Y. (2026). Site-specific heterogeneity of genomic radiosensitivity across primary tumors, regional and distant metastases in breast cancer. Clinical Oncology, 104372. https://doi.org/10.1016/j.clon.2026.104372

Vancouver

Loap P, Crehange G, Kirova Y. Site-specific heterogeneity of genomic radiosensitivity across primary tumors, regional and distant metastases in breast cancer. Clinical Oncology. 2026:104372. doi:10.1016/j.clon.2026.104372

BibTeX
@article{Loap2026,
  author = {Loap, Pierre and Crehange, Gilles and Kirova, Youlia},
  title = {Site-specific heterogeneity of genomic radiosensitivity across primary tumors, regional and distant metastases in breast cancer},
  journal = {Clinical Oncology},
  year = {2026},
  pages = {104372},
  doi = {10.1016/j.clon.2026.104372}
}
Kostenlos starten →